Involvement of gag- and env-specific cytotoxic T lymphocytes in protective immunity to feline immunodeficiency virus.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Involvement of gag- and env-specific cytotoxic T lymphocytes in protective immunity to feline immunodeficiency virus.

AIDS Res Hum Retroviruses. 1995 Sep;11(9):1107-13. Unique Identifier : AIDSLINE MED/96089218
Flynn JN; Beatty JA; Cannon CA; Stephens EB; Hosie MJ; Neil JC; Jarrett O; Department of Veterinary Pathology, University of Glasgow,; Bearsden, Scotland.

Abstract: Definition of the immunological mechanisms involved in protective immunity against lentiviral infections is crucial to the development of an effective vaccine. The induction of gag- and env-specific cell-mediated immune responses was studied in cats following vaccination with whole inactivated feline immunodeficiency virus (FIV). Cats were immunized by inoculation with three doses of paraformaldehyde-inactivated FIV, derived from the feline lymphoid cell line, FL-4, which is persistently infected with the Petaluma isolate of FIV. Autologous or allogeneic skin fibroblasts either infected with recombinant FIV gag- or env-vaccinia virus or pulsed with FIV env peptides were used as targets in chromium-51 release assays. Effector cells were fresh peripheral blood mononuclear cells. Following the third immunization, all vaccinated cats, but none of the control cats immunized with adjuvant alone, had detectable FIV env-specific lymphocytotoxicity in their peripheral blood. Two cats also exhibited gag-specific activity. There was no recognition of either allogeneic skin fibroblasts infected with recombinant vaccinia virus or autologous target cells infected with wild-type vaccinia virus, indicating the specificity and MHC-restricted nature of the response. Vaccinated cats, but not control cats, were protected from challenge with the homologous Petaluma isolate of FIV. Partial epitope mapping of the env-specific cytotoxic response was performed using overlapping 10-amino acid peptides from the env V3 domain of FIV. This response appeared to be directed at env peptide 1 (RAISSWKQRN) and env peptide 3 (QRNRWEWRPD), which lie adjacent to a beta-turn within the V3 domain.(ABSTRACT TRUNCATED AT 250 WORDS)

Keywords: Amino Acid Sequence Animal Antibodies, Viral/BLOOD Cats Epitope Mapping Feline Acquired Immunodeficiency Syndrome/IMMUNOLOGY/PREVENTION & CONTROL Gene Products, env/GENETICS/*IMMUNOLOGY Gene Products, gag/BLOOD/GENETICS/*IMMUNOLOGY Immunodeficiency Virus, Feline/GENETICS/*IMMUNOLOGY Molecular Sequence Data Peptide Fragments/GENETICS/IMMUNOLOGY Support, Non-U.S. Gov't T-Lymphocytes, Cytotoxic/*IMMUNOLOGY Vaccination Vaccines, Inactivated/PHARMACOLOGY Viral Vaccines/PHARMACOLOGY JOURNAL ARTICLE
960530
M9651088

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .